PM

Prosight Management Portfolio holdings

AUM $580M Turnover 39.22%
1-Year Est. Return 29.81%
This Fund
S&P 500
This Quarter Est. Return
+1.17%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$406M
AUM Growth
+$71.8M
Cap. Flow
+$62M
Cap. Flow %
15.25%
Top 10 Hldgs %
55.4%
Holding
62
New
16
Increased
17
Reduced
12
Closed
17
Avg Time Held Equity + Options
0.7 years
Top 10 Avg Time Held Equity + Options
0.7 years
Top 20 Avg Time Held Equity + Options
0.8 years
Avg Time Held Equity only
0.8 years
Top 10 Avg Time Held Equity only
0.7 years
Top 20 Avg Time Held Equity only
0.8 years

Top Buys

Rank Stock Value
1
MCK icon
McKesson
MCK
+$19.9M
2
ABCL icon
AbCellera Biologics
ABCL
+$18.6M
3
DXCM icon
DexCom
DXCM
+$9.09M
4
JANX icon
Janux Therapeutics
JANX
+$8.92M
5
BBIO icon
BridgeBio Pharma
BBIO
+$7.53M

Top Sells

Rank Stock Value
1
KELYA icon
Kelly Services Class A
KELYA
+$10.5M
2
LKFT icon
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$8.74M
3
ALKS icon
Alkermes
ALKS
+$6.63M
4
KIDS icon
OrthoPediatrics
KIDS
+$5.76M
5
OPCH icon
Option Care Health
OPCH
+$5.68M

Sector Composition

Rank Sector Weight
1 Healthcare 94.39%
2 Miscellaneous 2.95%
3 Industrials 2.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ADCT icon
1
ADC Therapeutics
ADCT
$185M
$30.4M 7.47%
9,636,237
+66,237
+0.7% +$209K
2022 Q3
8 quarters
LKFT icon
2
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.93B
$29.6M 7.29%
1,028,843
-321,137
-24% -$8.74M
2021 Q1
14 quarters
BBIO icon
3
BridgeBio Pharma
BBIO
$12.7B
$27.7M 6.81%
1,086,810
+286,810
+36% +$7.53M
2024 Q1
2 quarters
ABCL icon
4
AbCellera Biologics
ABCL
$4.01B
$23.6M 5.81%
9,079,539
+6,726,906
+286% +$18.6M
2022 Q3
8 quarters
MGTX icon
5
MeiraGTx Holdings
MGTX
$904M
$20.4M 5.03%
4,900,570
+547,870
+13% +$2.37M
2022 Q1
10 quarters
ROIV icon
6
Roivant Sciences
ROIV
$24.3B
$19.9M 4.89%
1,721,512
-278,488
-14% -$3.17M
2024 Q1
2 quarters
STTK icon
7
Shattuck Labs
STTK
$535M
$19.8M 4.88%
5,678,726
+1,008,726
+22% +$3.76M
2021 Q3
12 quarters
MIRM icon
8
Mirum Pharmaceuticals
MIRM
$5.19B
$18.2M 4.47%
465,825
+151,025
+48% +$6.02M
2022 Q1
10 quarters
ZBH icon
9
Zimmer Biomet
ZBH
$17.5B
$17.9M 4.4%
165,602
-4,398
-3% -$480K
2024 Q1
2 quarters
MCK icon
10
McKesson
MCK
$114B
$17.7M 4.36%
+35,822
New +$19.9M
2024 Q3
0 quarters
KURA icon
11
Kura Oncology
KURA
$855M
$13.8M 3.39%
705,109
+75,209
+12% +$1.52M
2023 Q2
5 quarters
SDGR icon
12
Schrodinger
SDGR
$1.87B
$13M 3.2%
700,000
+330,739
+90% +$6.79M
2024 Q2
1 quarter
ZYME icon
13
Zymeworks
ZYME
$1.78B
$11.5M 2.83%
917,599
-262,401
-22% -$2.86M
2024 Q1
2 quarters
ACCD icon
14
DELISTED
Accolade Inc
ACCD
$10.8M 2.65%
2,801,598
+1,312,073
+88% +$5.14M
2024 Q2
1 quarter
DXCM icon
15
DexCom
DXCM
$31.5B
$10.7M 2.64%
160,000
+110,683
+224% +$9.09M
2023 Q3
4 quarters
SNDX icon
16
Syndax Pharmaceuticals
SNDX
$1.21B
$10.7M 2.62%
554,103
+2,559
+0.5% +$52.9K
2024 Q2
1 quarter
IMVT icon
17
Immunovant
IMVT
$5.76B
$10.5M 2.6%
370,000
+45,000
+14% +$1.33M
2024 Q1
2 quarters
CYTK icon
18
Cytokinetics
CYTK
$8.82B
$10.2M 2.5%
192,700
-37,300
-16% -$2.08M
2024 Q1
2 quarters
JANX icon
19
Janux Therapeutics
JANX
$1.05B
$9.31M 2.29%
+205,000
New +$8.92M
2024 Q3
0 quarters
PRTA icon
20
Prothena Corp
PRTA
$430M
$8.09M 1.99%
483,467
+196,541
+68% +$4.23M
2020 Q3
16 quarters
NBIX icon
21
Neurocrine Biosciences
NBIX
$13.8B
$7.14M 1.76%
62,000
+35,000
+130% +$4.8M
2023 Q1
6 quarters
OEF icon
22
PUT
iShares S&P 100 ETF
OEF
$20.6B
$6.41M 1.58%
+29,000
New +$7.75M
2024 Q3
0 quarters
ERAS icon
23
Erasca
ERAS
$5.14B
$5.42M 1.33%
1,984,010
-765,990
-28% -$2.16M
2023 Q1
6 quarters
HAE icon
24
Haemonetics
HAE
$5.51B
$5.22M 1.29%
+65,000
New +$5.25M
2024 Q3
0 quarters
LIVN icon
25
LivaNova
LIVN
$4.19B
$4.73M 1.16%
+90,000
New +$4.46M
2024 Q3
0 quarters
1
2 3

Similar funds

SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
COFG Advisors Oak Brook, Illinois $579M AUM

Prosight Management's Q3 2024 Portfolio in Review

As of Q3 2024, Prosight Management held 62 positions worth $406M, up 21% from $335M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Prosight Management deployed $62M of net new capital in Q3 2024, opening 16 new positions and adding to 17 existing holdings. Its largest new stake was McKesson: 35,822 shares worth $17.7M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Miscellaneous and Industrials.

On the sell side, the largest reduction was Lakefront Biotherapeutics American Depositary Shares, an estimated $8.74M trimmed.

  • Prosight Management's largest Q3 2024 buy was McKesson: 35,822 shares worth $17.7M.
  • Prosight Management added most to AbCellera Biologics in Q3 2024, an estimated $18.6M increase.
  • Prosight Management's biggest Q3 2024 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $8.74M.
  • Prosight Management fully exited Kelly Services Class A in Q3 2024, selling an estimated $10.5M.
  • Prosight Management's ten largest holdings make up 55% of its $406M portfolio in Q3 2024.
  • Prosight Management opened 16 new positions and closed 17 in Q3 2024.
  • Prosight Management's portfolio value rose 21% quarter-over-quarter to $406M.

Based on Prosight Management's 13F filing for Q3 2024, filed 14 Nov 2024.